title: Qualitative and quantitative HIV antibodies and viral reservoir size characterization in vertically infected children with virological suppression.
abstract: Absence of detectable viraemia after treatment cessation in some vertically HIV-infected (VHIV) children suggests that early initiation of HAART could lead to functional cure.
  
  
  
  We described the factors associated with HIV antibody levels and the viral reservoir size in HAART-treated VHIV children.
  
  
  
  Study included 97 VHIV children with virological suppression, in Bamako, Mali. The anti-gp41 antibody activities and HIV serostatus were assessed. The viral reservoir size was measured by quantifying total cell-associated HIV DNA.
  
  
  
  Among the children studied, the median total HIV DNA level was 445 copies/10 6 cells (IQR = 187-914) and the median anti-gp41 antibody activity was 0.29 OD (IQR = 0.18-0.75). Low activity of anti-gp41 antibodies was associated with a younger age of HAART initiation ( P  =   0.01). Overall, eight HIV-1 seroreversions were identified.
  
  
  
  Study identified potential candidates with low viral reservoir and low antibody levels or activities for future trials aiming to reduce HIV-1 reservoir to limit HAART duration.
authors.affiliation: Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris F75013, France.|Department of Virology, Hôpital Pitié-Salpêtrière, AP-HP, Paris F75013, France.
authors.forename: Josephine
authors.initials: J
authors.lastname: Brice
authors.affiliation: Department of Pediatric, University Hospital Gabriel Toure, Bamako, Mali.
authors.forename: Mariam
authors.initials: M
authors.lastname: Sylla
authors.affiliation: Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris F75013, France.|Department of Virology, Hôpital Pitié-Salpêtrière, AP-HP, Paris F75013, France.
authors.forename: Sophie
authors.initials: S
authors.lastname: Sayon
authors.affiliation: Unité d'Epidémiologie Moléculaire de la Résistance du VIH aux ARV, SEREFO, FMOS, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
authors.forename: Fatoumata
authors.initials: F
authors.lastname: Telly
authors.affiliation: Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris F75013, France.|Department of Virology, Hôpital Pitié-Salpêtrière, AP-HP, Paris F75013, France.
authors.forename: Djeneba
authors.initials: D
authors.lastname: Bocar-Fofana
authors.affiliation: Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, 645 N Michigan Avenue, Suite 900, Chicago, IL 60611, USA.
authors.forename: Robert
authors.initials: R
authors.lastname: Murphy
authors.affiliation: Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris F75013, France.|Department of Virology, Hôpital Pitié-Salpêtrière, AP-HP, Paris F75013, France.
authors.forename: Sidonie
authors.initials: S
authors.lastname: Lambert-Niclot
authors.affiliation: Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris F75013, France.|Department of Virology, Hôpital Pitié-Salpêtrière, AP-HP, Paris F75013, France.
authors.forename: Eve
authors.initials: E
authors.lastname: Todesco
authors.affiliation: Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris F75013, France.|Department of Virology, Hôpital Pitié-Salpêtrière, AP-HP, Paris F75013, France.
authors.forename: Maxime
authors.initials: M
authors.lastname: Grude
authors.affiliation: CHRU de Tours, French reference centre of HIV, Virologic laboratory, Tours, France.
authors.forename: Francis
authors.initials: F
authors.lastname: Barin
authors.affiliation: Unité d'Epidémiologie Moléculaire de la Résistance du VIH aux ARV, SEREFO, FMOS, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
authors.forename: Souleymane
authors.initials: S
authors.lastname: Diallo
authors.affiliation: Africa Health Research Institute, Durban, South Africa.
authors.forename: Deenan
authors.initials: D
authors.lastname: Pillay
authors.affiliation: Africa Health Research Institute, Durban, South Africa.
authors.forename: Anne
authors.initials: A
authors.lastname: Derache
authors.affiliation: Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris F75013, France.|Department of Virology, Hôpital Pitié-Salpêtrière, AP-HP, Paris F75013, France.
authors.forename: Vincent
authors.initials: V
authors.lastname: Calvez
authors.affiliation: Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris F75013, France.|Department of Virology, Hôpital Pitié-Salpêtrière, AP-HP, Paris F75013, France.
authors.forename: Anne-Geneviève
authors.initials: AG
authors.lastname: Marcelin
authors.affiliation: Unité d'Epidémiologie Moléculaire de la Résistance du VIH aux ARV, SEREFO, FMOS, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.|Clinical and Microbiology Laboratory, University Hospital Gabriel Toure, Bamako, Mali.
authors.forename: Almoustapha Issiaka
authors.initials: AI
authors.lastname: Maiga
mesh_terms: D000293:Adolescent; D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D005260:Female; D015483:HIV Antibodies / Q000097:blood*; D015658:HIV Infections / Q000276:immunology* / Q000635:transmission / Q000821:virology*; D015497:HIV-1 / Q000276:immunology / Q000502:physiology*; D006801:Humans; D018445:Infectious Disease Transmission, Vertical; D008297:Male; D011446:Prospective Studies; D019562:Viral Load; D014766:Viremia / Q000276:immunology; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents; D015483:HIV Antibodies